Future prospect of insulin inhalation for diabetic patients: The case of Afrezza versus Exubera

Journal of Controlled Release

Volumn 215, Issue , 2015, Pages 25-38

  Al Tabakha, Moawia M ^a  

^a AL AIN UNIVERSITY   (United Arab Emirates)

Author keywords

Diabetes mellitus; Insulin inhalation pharmacodynamics; Insulin inhalation pharmacokinetics; Insulin inhalation safety; Insulin inhalers; Insulin types

Indexed keywords

BIOCHEMISTRY; COMMERCE; DRUG PRODUCTS; PATIENT TREATMENT;

CLINICAL DEVELOPMENT; DIABETES MELLITUS; DIABETIC PATIENT; FUTURE PROSPECTS; INSULIN INJECTIONS; INSULIN THERAPY; PHARMACEUTICAL COMPANY; SYSTEMATIC REVIEW;

INSULIN;

CARBON MONOXIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ANTIBODY; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT; SHORT ACTING INSULIN;

CARDIOVASCULAR RISK; COUGHING; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IMMUNOGENICITY; INHALER; INSULIN RELEASE; INSULIN TREATMENT; LUNG CANCER; LUNG CAPACITY; LUNG FUNCTION TEST; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN; ANIMAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER;

ADMINISTRATION, INHALATION; ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, SHORT-ACTING; NEBULIZERS AND VAPORIZERS;

EID: 84939441690     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.07.025     Document Type: Review

References (116)

1. M. Ibrahim, R. Verma, and L. Garcia-Contreras Inhalation drug delivery devices: technology update Med. Devices 8 2015 131 139
2. J. Rashid, S. Absar, K. Nahar, N. Gupta, and F. Ahsan Newer devices and improved formulations of inhaled insulin Expert Opin. Drug Deliv. 2014 1 12
3. A. Mahmud, and D.E. Discher Lung vascular targeting through inhalation delivery: insight from filamentous viruses and other shapes IUBMB Life 63 2011 607 612
4. R.I. Henkin Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: mechanisms of action Nutrition 26 2010 33 39
5. R.R. Rubin, M. Peyrot, D.F. Kruger, and L.B. Travis Barriers to insulin injection therapy: patient and health care provider perspectives Diabetes Educ. 35 2009 1014 1022
6. el-S. Khafagy, M. Morishita, Y. Onuki, and K. Takayama Current challenges in non-invasive insulin delivery systems: a comparative review Adv. Drug Deliv. Rev. 59 2007 1521 1546
7. D.F. Kruger, S. LaRue, and P. Estepa Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment Diabetes Metab. Syndr. Obes. Targets Ther. 8 2015 49 56
8. M. Peyrot, R.R. Rubin, and K. Khunti Addressing barriers to initiation of insulin in patients with type 2 diabetes Prim. Care Diabetes 4 Suppl. 1 2010 S11 S18
9. A.J. Karter, U. Subramanian, C. Saha, J.C. Crosson, M.M. Parker, B.E. Swain, H.H. Moffet, and D.G. Marrero Barriers to insulin initiation: the translating research into action for diabetes insulin starts project Diabetes Care 33 2010 733 735
10. V. Alabraba, A. Farnsworth, R. Leigh, P. Dodson, S.C. Gough, and T. Smyth Exubera inhaled insulin in patients with type 1 and type 2 diabetes: the first 12 months Diabetes Technol. Ther. 11 2009 427 430
11. G.S.R. Siekmeier Inhaled insulin - does it become reality? J. Physiol. Pharmacol. 59 2008 81 113
12. M.M. Al-Tabakha, and A.I. Arida The effects of capsule fill weight and drug/carrier blend ratio on the aerosolization of a model drug from a Spinhaler™ Saudi Pharm. J. 15 2007 127
13. M. Al-Tabakha, and A. Arida A Study of the Effect of Jet Milling Process With or Without Pre-treatment on Aerosolisation Characteristics of FITC-Dextran Particles 2006
14. A.M. Healy, M.I. Amaro, K.J. Paluch, and L. Tajber Dry powders for oral inhalation free of lactose carrier particles Adv. Drug Deliv. Rev. 75 2014 32 52
15. M. Hoppentocht, P. Hagedoorn, H.W. Frijlink, and A.H. de Boer Technological and practical challenges of dry powder inhalers and formulations Adv. Drug Deliv. Rev. 75 2014 18 31
16. H. Okamoto, and K. Danjo Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation Adv. Drug Deliv. Rev. 60 2008 433 446
17. M.M. Al-Tabakha HPMC capsules: current status and future prospects J. Pharm. Pharm. Sci. 13 2010 428 442
18. C. de Souza Carvalho, N. Daum, and C.M. Lehr Carrier interactions with the biological barriers of the lung: advanced in vitro models and challenges for pulmonary drug delivery Adv. Drug Deliv. Rev. 75 2014 129 140
19. M.T. Marino, J.P. Cassidy, C.C. Smutney, M. Zupon, and J. Kocinski Bioequivalence and Dose Proportionality of AFREZZA® Inhalation Powder Administered Using a Gen2 Inhaler Compared to the MedTone® Inhaler 2010 MannKind Corporation Bethesda, MD
20. M. Corporation Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-Week Treatment Period 2011 U.S. National Library of Medicine
21. A.D. Perera, C. Kapitza, L. Nosek, R.S. Fishman, D.A. Shapiro, T. Heise, and L. Heinemann Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes Diabetes Care 25 2002 2276 2281
22. L.D. Mastrandrea, and T. Quattrin Clinical evaluation of inhaled insulin Adv. Drug Deliv. Rev. 58 2006 1061 1075
23. J.M. Tibaldi Evolution of insulin development: focus on key parameters Adv. Ther. 29 2012 590 619
24. J.J. Neumiller, and R.K. Campbell Technosphere insulin: an inhaled prandial insulin product BioDrugs 24 2010 165 172
25. H. Zisser, E. Dassau, J.J. Lee, R.A. Harvey, W. Bevier, and F.J. Doyle 3rd Clinical results of an automated artificial pancreas using Technosphere inhaled insulin to mimic first-phase insulin secretion J. Diabetes Sci. Technol. 9 2015 564 572
26. J.J. Neumiller, R.K. Campbell, and L.D. Wood A review of inhaled Technosphere insulin Ann. Pharmacother. 44 2010 1231 1239
27. F. Depreter, A. Burniat, D. Blocklet, S. Lacroix, M. Cnop, F. Fery, N.V. Aelst, G. Pilcer, M. Deleers, S. Goldman, and K. Amighi Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients Eur. J. Pharm. Biopharm. 80 2012 4 13
28. Insulin inhalation - Pfizer/Nektar Therapeutics: HMR 4006, inhaled PEG-insulin-Nektar, PEGylated insulin-Nektar Drugs R D 5 2004 166 170
29. A.J. Kugler, K.L. Fabbio, D.Q. Pham, and D.A. Nadeau Inhaled Technosphere insulin: a novel delivery system and formulation for the treatment of types 1 and 2 diabetes mellitus Pharmacotherapy 35 2015 298 314
30. C.J. Bailey, and A.H. Barnett Why is Exubera being withdrawn? BMJ 335 2007 1156
31. L. Heinemann The failure of Exubera: are we beating a dead horse? J. Diabetes Sci. Technol. 2 2008 518 529
32. H.W.J. Shih New technologies for insulin administration and glucose monitoring C.C. Richard, I.G. Holt, Allan Flyvbjerg, Barry J. Goldstein, Textbook of Diabetes 2010 Wiley-Blackwell West Sussex, UK 440 451
33. H.C. Fantasia Inhaled insulin - a new delivery for an old drug Nurs. Womens Health 19 2015 67 70
34. C.C. Smutney, J.M. Polidoro, P.S. Kinsey, and B. Adamo Dry Powder Inhaler U.S.P.a.T. Office 2010 MannKind Corporation USA (http://www.uspto.gov/)
35. P.J. Kuehl, A. Cherrington, D.E. Dobry, D. Edgerton, D.T. Friesen, C. Hobbs, C.L. Leach, B. Murri, D. Neal, D.K. Lyon, D.T. Vodak, and M.D. Reed Biologic comparison of inhaled insulin formulations: Exubera and novel spray-dried engineered particles of dextran-10 AAPS PharmSciTech 15 2014 1545 1550
36. P.F. Hite, A.M. Barnes, and P.E. Johnston Exhuberance over Exubera Clin. Diabetes 24 2006 110 114
37. M.M. Al-Tabakha, and A.I. Arida Recent challenges in insulin delivery systems: a review Indian J. Pharm. Sci. 70 2008 278 286
38. A.H. Barnett Exubera inhaled insulin: a review Int. J. Clin. Pract. 58 2004 394 401
39. M. Rendell Technosphere inhaled insulin (Afrezza) Drugs Today 50 2014 813 827
40. A. Leone-Bay, R. Baughman, C. Smutney, J. Kocinsky, and MannKind Corporation Innovation in drug delivery by inhalation ONdrugDelivery Magazine 2010 Frederick Furness Publishing United Kingdom 4 8
41. M.S. Bergey Blister Packaging U.S.P.a.T. Office 2011 MannKind Corporation USA
42. M.C. Metabolic and Drug Advisory Committee AFREZZA® (Insulin Human [rDNA Origin]) Inhalation Powder: An Ultra-rapid Acting Insulin Treatment to Improve Glycemic Control in Adult Patients with Diabetes Mellitus 2014 MannKind Corporation 1 217 (http://www.fda.gov)
43. M. Corporation Device Technology: Patient-focused Dry Powder Inhalers 2011 MannKind Corporation (http://www.mannkindcorp.com/)
44. D. Singh-Franco All About Afrezza®: The New Insulin Inhalation Powder 2014 Medscape 1 5
45. M. Corporation US Package Insert for Afrezza 2014 1 35 (www.fda.gov)
46. U.S. Package Insert for Exubera in: www.fda.gov 2006 Pfizer 1 24
47. M.J. Pfeffer, and MannKind Corporation MannKind to Manufacture 12 Unit Cartridge Strength of Afrezza Following FDA Approval MannKind 2015 GLOBE NEWSWIRE
48. Sanofi and MannKind Corporation Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S. Sanofi and MannKind Corporation 2015 Sanofi (http://en.sanofi.com/)
49. U. Pharmacists Insulin Inhaled 2015 National Health Service New Drugs Online
50. News and Information for Medical Professionals Exubera Inhaled Insulin Is No Longer Available 2007 Diabetes in Control, Issue 387, HIPER, LLC.
51. T.J. Elena Chan Exubera® Insulin Human (rDNA origin) Inhalation Powder, in, P & T Committee Formulary Review Pro Pharma Pharmaceutical Consultants, Inc. 2006
52. B.M.K., Lisa S. Rotenstein, Joseph P. Shivers, Mark Yarchoan, John Close, and Kelly L. Close The ideal diabetes therapy: what will it look like? How close are we? Clin. Diabetes 30 2012 44 53
53. G.S. Mack Pfizer dumps Exubera Nat. Biotechnol. 25 2007 1331 1332
54. T. Staton UPDATED: Goldman Cuts Afrezza Sales Forecast in Half on Slow Uptake, Pricing Pressure 2015 FierceMarkets
55. G. NEWSWIRE MannKind Corporation Reports 2015 First Quarter Financial Results 2015 MannKind Corporation
56. D. Stanton MannKind: Afrezza's Slow Start Due to Delays Not Demand for Inhalable Insulin 2015 In-Pharma Technologist
57. S. Deepak MannKind Corporation (MNKD) Stock Climbs On Physician Feedback 2015
58. C.B. Landersdorfer, and W.J. Jusko Pharmacokinetic/pharmacodynamic modeling of glucose clamp effects of inhaled and subcutaneous insulin in healthy volunteers and diabetic patients Drug Metab. Pharmacokinet. 25 2010 418 429
59. M.H. Becquemin, and J.P. Chaumuzeau Inhaled insulin: a model for pulmonary systemic absorption? Rev. Mal. Respir. 27 2010 e54 e65
60. H.-Y.A., and Sayed (Sam) Al Habet Clinical pharmacology and biopharmaceutics review on Exubera Executive Summary for Advisory Committee 2005 1 9 (FDA.Gov)
61. F.A. Committee FDA Briefing Document: New Drug Application (NDA) 022472, Proposed Trade Name Afrezza (Technosphere Insulin Inhalation System) 2014 FDA
62. N.H. White, T. Quattrin, L.B. St Aubin, W.T. Duggan, R.D. England, and J.S. Fryburg Efficacy and safety of inhaled human insulin (Exubera) compared to subcutaneous insulin in children ages 6 to 11 years with type 1 diabetes mellitus: results of a 3-month, randomized, parallel trial J. Pediatr. Endocrinol. Metab. 21 2008 555 568
63. S. Wise, J. Chien, K. Yeo, and C. Richardson Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system Diab. Med. 23 2006 510 515
64. K. Rave, S. Bott, L. Heinemann, S. Sha, R.H. Becker, S.A. Willavize, and T. Heise Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin Diabetes Care 28 2005 1077 1082
65. P.A. Hollander Evolution of a pulmonary insulin delivery system (Exubera) for patients with diabetes MedGenMed 9 2007 45
66. Keith A. Markey MannKind Corporation: Pharmaceutical Industry Update Report 2011 Griffin Securities
67. L. France Eli Lilly, Humalog Insulin Lispro Injection; (rDNA Origin); U-100, in: I. Eli Lilly and Company, IN 46285, USA FDA 2007 1 5
68. A.H. Boss, R. Petrucci, and D. Lorber Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin J. Diabetes Sci. Technol. 6 2012 773 779
69. A. Leone-Bay, R. Baughman, C. Smutney, J. Kocinsky, and MannKind Corporation Innovation in Drug Delivery By Inhalation 2010 Frederick Furness Publishing 4 8
70. L. Online® Lexi-Drugs Multinational, in, Lexi-Comp, Inc. 2015 Hudson Ohio
71. K.M. Mahoney Initial Clinical Review for Inclusion in Advisory Committee Briefing Document on Exubera NDA 2004 FDA
72. N.N. Inc. NovoLog® Insulin aspart (rDNA origin) Injection Product Label, in, FDA 2008 1 16
73. E.M. Agency Scientific Discussion on Exubera 2006 European Medicines Agency 1 57
74. C.O. Mendivil, J.G. Teeter, G.L. Finch, P.F. Schwartz, R.J. Riese, and J.D. Brain Trough insulin levels in bronchoalveolar lavage following inhaled human insulin (Exubera) in patients with diabetes mellitus Diabetes Technol. Ther. 14 2012 50 58
75. P. Aschner, B. Sethi, F. Gomez-Peralta, W. Landgraf, V. Loizeau, M.P. Dain, V. Pilorget, and A. Comlekci Insulin glargine compared with premixed insulin for management of insulin-naive type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study J. Diabetes Complicat. 29 6 2015 838 845
76. L.D. Mastrandrea Inhaled insulin: overview of a novel route of insulin administration Vasc. Health Risk Manag. 6 2010 47 58
77. P.A. Hollander, W.T. Cefalu, M. Mitnick, D. Lawrence, and J. Rosenstock Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 diabetes Diabetes Technol. Ther. 12 2010 185 191
78. M. Corporation Patient Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder 2008 U.S. National Library of Medicine
79. Pfizer Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes 2006 U.S. National Library of Medicine
80. Pfizer A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®, in, U.S National Library of Medicine 2008
81. Pfizer This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus 2007 U.S. National Library of Medicine
82. Pfizer Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety 2006 National Library of Medicine (NLM)
83. Pfizer A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma 2003 U.S. National Library of Medicine
84. M. Corporation Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus 2011 U.S. National Library of Medicine
85. M. Corporation Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes 2006 U.S. National Library of Medicine
86. M. Corporation Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up 2006 U.S. National Library of Medicine
87. M. Corporation A Four-year, Safety and Tolerability, Open-Label, "Follow on" Trial Evaluating Technosphere® Insulin in Subjects With Type 2 Diabetes Mellitus 2004 U.S. National Library of Medicine
88. C.A. Lasagna-Reeves, A.L. Clos, T. Midoro-Hiriuti, R.M. Goldblum, G.R. Jackson, and R. Kayed Inhaled insulin forms toxic pulmonary amyloid aggregates Endocrinology 151 2010 4717 4724
89. D.F. Kruger Intensifying insulin treatment: options, practical issues, and the role of the nurse practitioner J. Am. Acad. Nurse Pract. 24 Suppl. 1 2012 260 269
90. P. Paganin, E.V. Fiscarelli, V. Tuccio, M. Chiancianesi, G. Bacci, P. Morelli, D. Dolce, C. Dalmastri, A. De Alessandri, V. Lucidi, G. Taccetti, A. Mengoni, and A. Bevivino Changes in cystic fibrosis airway microbial community associated with a severe decline in lung function PLoS One 10 2015 e0124348
91. S. Dubsky, and A. Fouras Imaging regional lung function: a critical tool for developing inhaled antimicrobial therapies Adv. Drug Deliv. Rev. 85 2015 100 109
92. M.H. Black, A. Anderson, R.A. Bell, D. Dabelea, C. Pihoker, S. Saydah, M. Seid, D.A. Standiford, B. Waitzfelder, S.M. Marcovina, and J.M. Lawrence Prevalence of asthma and its association with glycemic control among youth with diabetes Pediatrics 128 2011 e839 e847
93. Z.T. Bloomgarden Afrezza: some questions about a new approach to prandial insulin J. Diabetes 6 2014 489 490
94. Pfizer Exubera Large Simple Trial to Evaluate Long-Term Pulmonary and Cardiovascular Safety July 2006 U.S. National Library of Medicine
95. M. Corporation Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes 2005 U.S. National Library of Medicine
96. P. Raskin, S. Heller, M. Honka, P.C. Chang, A.H. Boss, P.C. Richardson, and N. Amin Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere insulin or usual antidiabetes treatment: a randomized trial Diabetes Obes. Metab. 14 2012 163 173
97. M. Corporation A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30 Units) With an Injection of Insulin Lispro 2008 U.S. National Library of Medicine
98. C. Crudden, A. Girnita, and L. Girnita Targeting the IGF-1R: the tale of the tortoise and the hare Front. Endocrinol. 6 2015 64
99. Pfizer Follow-Up Study for Exubera 2008 U.S. National Library of Medicine
100. A. Jemal, M.J. Thun, L.A. Ries, H.L. Howe, H.K. Weir, M.M. Center, E. Ward, X.C. Wu, C. Eheman, R. Anderson, U.A. Ajani, B. Kohler, and B.K. Edwards Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control J. Natl. Cancer Inst. 100 2008 1672 1694
101. M.W. Marcus, O.Y. Raji, and J.K. Field Lung cancer screening: identifying the high risk cohort J. Thorac. Dis. 7 2015 S156 S162
102. L. Heinemann, and D.B. Muchmore Ultrafast-acting insulins: state of the art J. Diabetes Sci. Technol. 6 2012 728 742
103. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes 2008 1 5
104. L. Razavi Nematollahi, and A.E. Kitabchi Hyperglycemic Crises: Diabetic Ketoacidosis (DKA), and Hyperglycemic Hyperosmolar State (HHS) L.J. De Groot, P. Beck-Peccoz, G. Chrousos, K. Dungan, A. Grossman, J.M. Hershman, C. Koch, R. McLachlan, M. New, R. Rebar, F. Singer, A. Vinik, M.O. Weickert, 2000 Endotext South Dartmouth (MA)
105. J.R. Sa, M.A. Alvarenga, E.B. Rangel, C.S. Melaragno, A.M. Gonzalez, M.M. Linhares, A. Salzedas, A.K. Carmona, V. Tonetto-Fernandes, M.A. Gabbay, J.O. Medina Pestana, and S.A. Dib Extreme subcutaneous, intramuscular and inhaled insulin resistance treated by pancreas transplantation alone Am. J. Transplant. 10 2010 184 188
106. L.D. Mastrandrea A breath of life for inhaled insulin: severe subcutaneous insulin resistance as an indication? Pediatr. Diabetes 11 2010 377 379
107. H.T. Heng Quan, Qianrui Li, Jianwei Li, and Sheyu Li Immunological hypoglycemia associated with insulin antibodies induced by exogenous insulin in 11 Chinese patients with diabetes J. Diabetes Res. 2015 2015 (9 pp.)
108. R.R. Rubin, and M. Peyrot Factors associated with physician perceptions of and willingness to recommend inhaled insulin Curr. Med. Res. Opin. 27 2011 285 294
109. M. Peyrot, and R.R. Rubin Perceived medication benefits and their association with interest in using inhaled insulin in type 2 diabetes: a model of patients' cognitive framework Patient Prefer. Adherence 5 2011 255 265
110. M. Peyrot, and R.R. Rubin Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled Technosphere insulin and basal insulin versus premixed insulin Diabetes Technol. Ther. 13 2011 1201 1206
111. M. Peyrot, and R.R. Rubin Effect of Technosphere inhaled insulin on quality of life and treatment satisfaction Diabetes Technol. Ther. 12 2010 49 55
112. T. Santos Cavaiola, and S. Edelman Inhaled insulin: a breath of fresh air? A review of inhaled insulin Clin. Ther. 36 2014 1275 1289
113. F. Petrak, S. Herpertz, E. Stridde, and A. Pfutzner Psychological insulin resistance in type 2 diabetes patients regarding oral antidiabetes treatment, subcutaneous insulin injections, or inhaled insulin Diabetes Technol. Ther. 15 2013 703 711
114. O.B. Ozoh, N.U. Okubadejo, C.C. Chukwu, and E.O. Bandele Eligibility of Nigerians with type 2 diabetes mellitus for inhaled insulin Niger. Q. J. Hosp. Med. 20 2010 77 80
115. C. Loira-Pastoriza, J. Todoroff, and R. Vanbever Delivery strategies for sustained drug release in the lungs Adv. Drug Deliv. Rev. 75 2014 81 91
116. L.W. Fleming, J.W. Fleming, and C.S. Davis Afrezza: an inhaled approach to insulin delivery J. Am. Assoc. Nurse Pract. 2015 10.1002/2327-6924.12247 (Epub ahead of print)